JP2017538711A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538711A5
JP2017538711A5 JP2017531306A JP2017531306A JP2017538711A5 JP 2017538711 A5 JP2017538711 A5 JP 2017538711A5 JP 2017531306 A JP2017531306 A JP 2017531306A JP 2017531306 A JP2017531306 A JP 2017531306A JP 2017538711 A5 JP2017538711 A5 JP 2017538711A5
Authority
JP
Japan
Prior art keywords
compound
compound according
chr
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017531306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538711A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/065109 external-priority patent/WO2016094729A1/en
Publication of JP2017538711A publication Critical patent/JP2017538711A/ja
Publication of JP2017538711A5 publication Critical patent/JP2017538711A5/ja
Pending legal-status Critical Current

Links

JP2017531306A 2014-12-10 2015-12-10 Glp−1レセプターモジュレーター Pending JP2017538711A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462090268P 2014-12-10 2014-12-10
US62/090,268 2014-12-10
US201562161658P 2015-05-14 2015-05-14
US62/161,658 2015-05-14
US201562164113P 2015-05-20 2015-05-20
US62/164,113 2015-05-20
PCT/US2015/065109 WO2016094729A1 (en) 2014-12-10 2015-12-10 Glp-1 receptor modulators

Publications (2)

Publication Number Publication Date
JP2017538711A JP2017538711A (ja) 2017-12-28
JP2017538711A5 true JP2017538711A5 (enExample) 2019-01-10

Family

ID=55069126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017531306A Pending JP2017538711A (ja) 2014-12-10 2015-12-10 Glp−1レセプターモジュレーター

Country Status (10)

Country Link
US (2) US9795613B2 (enExample)
EP (1) EP3230276B1 (enExample)
JP (1) JP2017538711A (enExample)
KR (1) KR102497644B1 (enExample)
AU (1) AU2015360364B2 (enExample)
CA (1) CA2969944A1 (enExample)
ES (1) ES2844573T3 (enExample)
IL (1) IL252565B (enExample)
MX (1) MX381977B (enExample)
WO (1) WO2016094729A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060424A1 (en) * 2017-04-28 2018-11-01 Celgene International Ii Sarl Novel glp-1 receptor modulators
WO2018215070A1 (en) * 2017-05-24 2018-11-29 Johann Wolfgang Goethe-Universität Frankfurt am Main Dual modulators of farnesoid x receptor and soluble epoxide hydrolase
CN113244208B (zh) * 2021-05-20 2022-07-12 云南中医药大学 Hpa在制备治疗非酒精性脂肪性肝病药物中的应用
WO2024210646A1 (ko) * 2023-04-05 2024-10-10 주식회사 아울바이오 Glp-1 수용체 작용제, gip/glp-1 수용체 이중작용제, 및 glp-1/gip/gcg 수용체 삼중작용제로 이루어진 군으로부터 선택되는 1종 이상을 포함하는 액상 제형 및 미립구 제형을 포함하는 약학 조성물
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
KR20250177377A (ko) * 2024-06-13 2025-12-23 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 당뇨 예방 또는 치료용 약학적 조성물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1062206B (it) 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2423536A1 (de) 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
HUP0003921A3 (en) 1997-07-31 2001-03-28 Wyeth Corp Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
ATE267801T1 (de) 1997-08-22 2004-06-15 Hoffmann La Roche N-alkanoylphenylalaninderivate
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
PL205713B1 (pl) 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
EP1150565A1 (en) * 1999-02-08 2001-11-07 LION bioscience AG Thiazole derivatives and combinatorial libraries thereof
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AU784827B2 (en) 2000-03-07 2006-06-29 Sanofi-Aventis Deutschland Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
JP4895067B2 (ja) * 2000-09-29 2012-03-14 味の素株式会社 新規フェニルアラニン誘導体
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
EP1477482B1 (en) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
AU2003235256A1 (en) * 2002-04-19 2003-11-03 Kyowa Hakko Kogyo Co., Ltd. Phenylalanine derivative
US20070276034A1 (en) 2002-05-31 2007-11-29 Luke Esposito Compounds, compositions and methods for the treatment of synucleinopathies
AR041137A1 (es) 2002-09-04 2005-05-04 Pharmacopeia Drug Discovery Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
MXPA05002571A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
US20040152750A1 (en) 2002-12-20 2004-08-05 Kodra Janos Tibor Novel glucagon antagonists
JP2006527233A (ja) 2003-06-13 2006-11-30 ラボラトリオス・エセ・ア・エレ・ベ・ア・テ・ソシエダッド・アノニマ PPARγ調節物質としての新規ベンズアミド
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
WO2005077915A1 (en) 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. Pyridazinones as antagonists of a4 integrins
WO2006117743A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Substituted aromatic compounds as antidiabetic agents
WO2006127595A1 (en) 2005-05-23 2006-11-30 Arena Pharmaceuticals, Inc. 5-aminopyrazole carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1878730A1 (en) 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
US8618324B2 (en) 2007-03-13 2013-12-31 Board Of Regents, The University Of Texas System Composition and method for making oligo-benzamide compounds
CA2688136A1 (en) 2007-06-08 2008-12-11 Advinus Therapeutics Private Limited Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
JP2013530963A (ja) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド 新規のglp−1受容体安定化薬および調節薬
EP2713722B1 (en) 2011-05-31 2017-03-15 Receptos, LLC Novel glp-1 receptor stabilizers and modulators
ES2836973T3 (es) 2011-12-12 2021-06-28 Receptos Llc Derivados de ácido carboxílico que comprenden cuatro ciclos que actúan como moduladores de receptor GLP-1 para la terapia de enfermedades tales como la diabetes
BR112015031040A8 (pt) 2013-06-11 2018-01-02 Receptos Inc Novos moduladores do receptor de glp-1
US9474755B2 (en) 2014-07-25 2016-10-25 Celgene International Ii Sarl GLP-1 receptor modulators

Similar Documents

Publication Publication Date Title
JP2016528180A5 (enExample)
JP2017526734A5 (enExample)
CA2724133C (en) Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine
JP2014527027A5 (enExample)
KR20220101075A (ko) Il-17a 조절인자 및 이의 용도
JP2015505842A5 (enExample)
JP2020507589A5 (enExample)
JP2010514829A5 (enExample)
JP2019520416A5 (enExample)
JP2014524472A5 (enExample)
RU2014111055A (ru) 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
RU2014128522A (ru) Новые модуляторы рецептора glp-1
JP2017531019A5 (enExample)
JP2019520417A5 (enExample)
EA032028B1 (ru) СТИМУЛЯТОРЫ рГЦ
JP2010514831A5 (enExample)
JP2008513496A5 (enExample)
JP2008513516A5 (enExample)
JP2012507566A5 (enExample)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2017524005A5 (enExample)
KR20190020170A (ko) 통풍 또는 고뇨산혈증과 관련된 증상의 치료 또는 예방을 위한 화합물, 조성물 및 방법
JP2011509309A5 (enExample)
RU2016105436A (ru) Нейроактивные стероиды, композиции и их использование
JP2020516591A (ja) Morアゴニストおよびkorアゴニストを含有する医薬組成物、およびその用途